CliffBio
biologic

Columvi

glofitamab-gxbm

Loss of exclusivityJune 2035projected — 12-year biologic exclusivity estimate
CompanyGenentech →See this company's full patent-cliff portfolio

Drug detail

Brand nameColumvi
Active ingredientglofitamab-gxbm
Strength2.5MG/2.5ML (1MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalJune 2023
Marketing statusRx

More from Genentech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.